<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01724866</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-GCF-12-201</org_study_id>
    <nct_id>NCT01724866</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients</brief_title>
  <official_title>Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of test doses of HM10460A on the duration
      of severe neutropenia (DSN) during Cycle 1 in patients with breast cancer who are candidates
      for adjuvant or neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multicenter, dose ranging study, sequentially enrolled by study dose,
      with a non-inferiority design to compare the effectiveness of HM10460A relative to a fixed
      dose of pegfilgrastim as a concurrent active control to each dose of HM10460A in patients
      with breast cancer. The study will include 4 arms: 3 dose levels of HM10460A versus
      pegfilgrastim. The start of study treatment is defined as the initiation of HM10460A or
      pegfilgrastim. The duration of treatment consists of a maximum of 4 cycles, which begin on
      Day 1 with chemotherapy administration and continue through Day 21.

      The planned number of patients is a total of 144 based on 36 enrolled into each of 4
      treatment arms. The target population are patients with breast cancer who are candidates for
      neoadjuvant or adjuvant treatment with TC chemotherapy. All patients who receive at least 1
      dose of either HM10460A or pegfilgrastim will be followed for safety through 20 (± 2) days
      after their last dose of study treatment or until all treatment-related AEs have resolved or
      returned to baseline/Grade 1, whichever is longer, or until it is determined that the outcome
      will not change with further follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of severe neutropenia (DSN) in Cycle 1</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>DSN in Cycle 1, with severe neutropenia defined as ANC &lt; 500 cells/μL (Grade 4 neutropenia, per NCI CTCAE). DSN is defined as the interval from the day of first observation of Grade 4 neutropenia to first ANC recovery to ≥ 2,000 cells/μL (Grade 0). Patients who do not present with Grade 4 neutropenia are censored in this analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Test Doses of HM10460A</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>To determine the effect of test doses of HM10460A on the DSN in Cycles 2-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Test Doses of HM10460A</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>To determine the effect of test doses of HM10460A on the absolute neutrophil count (ANC) in Cycles 1-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Test Doses of HM10460A</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>To determine the effect of test doses of HM10460A on the febrile neutropenia (FN) rates by cycle and overall across Cycles 1-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Test Doses of HM10460A</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>To determine the effect of test doses of HM10460A on the number/duration of hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Test Doses of HM10460A</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>To determine the effect of test doses of HM10460A on the:
• Immunogenicity : The immunogenicity blood sample will be collected to test for antibodies binding to HM10460A and native G-CSF on Day -1 of each cycle (prior to administration of corticosteroids) and at the End of Study Visit.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>Single-dose HM10460A (45 μg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose HM10460A (45 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-dose HM10460A (135 μg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose HM10460A (135 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-dose HM10460A (270 μg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose HM10460A (270 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegfilgrastim 6 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegfilgrastim (Neulasta®) is not to be administered between 14 days before or 24 hours after TC chemotherapy. Pegfilgrastim (Neulasta®) will be administered according to the manufacturer's Prescribing Information (6 mg subcutaneously once per chemotherapy cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A (45 μg/kg)</intervention_name>
    <description>Single-dose subcutaneous injection</description>
    <arm_group_label>Single-dose HM10460A (45 μg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A (135 μg/kg)</intervention_name>
    <description>Single-dose subcutaneous injection</description>
    <arm_group_label>Single-dose HM10460A (135 μg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM10460A (270 μg/kg)</intervention_name>
    <description>Single-dose subcutaneous injection</description>
    <arm_group_label>Single-dose HM10460A (270 μg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim 6mg</intervention_name>
    <description>Single-dose subcutaneous injection, per manufacturer's Prescribing Information</description>
    <arm_group_label>Pegfilgrastim 6 mg</arm_group_label>
    <other_name>Neulasta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed breast cancer who is a candidate for adjuvant or neoadjuvant
             chemotherapy

          -  Candidate for docetaxel and cyclophosphamide chemotherapy

          -  Female or male ≥ 18 years of age

          -  ECOG ≤ 2

          -  ANC ≥ 1.5 x 10^9/L

          -  Platelet count ≥ 100 x 10^9/L

          -  Creatinine ≤ 1.5 x upper limit of normal (ULN)

          -  Total bilirubin ≤ 1.5 mg/dL (≤ 25.65 μmol/L)

          -  AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN

          -  Hemoglobin &gt; 9 g/dL

          -  Alkaline phosphatase ≤ 1.5 x ULN

        Exclusion Criteria:

          -  Known sensitivity to E. coli derived products or known sensitivity to any of the
             products to be administered during dosing

          -  Known HIV infection

          -  HBV or HCV diagnosis with detectable viral load or immunological evidence of chronic
             active disease

          -  Active infection or any serious underlying medical condition, which would impair the
             ability of the patient to receive protocol treatment

          -  Prior bone marrow or stem cell transplant

          -  Prolonged exposure to glucocorticosteroids and immunosuppressive agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Niederman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emad Ibrahim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beaver Medical Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew J Buresh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Desert Springs Cancer Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy E Byun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Oncology Medical Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clarence S Adoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona Center for Cancer Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven J Hager, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Cancer Associates for Research and Excellence</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Warren S Paroly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North County Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael A Kosmo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Cancer Associates for Research and Excellence</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kimberly McGregor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Good Samaritan Hospital, Corvallis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Springs Cancer Care</name>
      <address>
        <city>Scottdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research and Excellence</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaver Medical Group</name>
      <address>
        <city>Highland</city>
        <state>California</state>
        <zip>92346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research and Excellence</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Medical Group</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer Institute</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward H. Kaplan MD &amp; Associates</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Cancer Clinic</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, PC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology/Oncology Associates</name>
      <address>
        <city>Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mark H. Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital, Corvallis</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Center Research</name>
      <address>
        <city>Kurralta Park</city>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breast Cancer Research Center, WA</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart</name>
      <address>
        <city>Tasmania</city>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ballarat Oncology &amp; Haematology</name>
      <address>
        <city>Wendouree</city>
        <zip>3355</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital</name>
      <address>
        <city>Mladá Boleslav</city>
        <zip>293 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD &quot; Cancer Center of Adjara Autonomic Republic&quot;</name>
      <address>
        <city>Batumi</city>
        <zip>6000</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC &quot; Neo Medi&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0131</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ltd &quot; High Technology Medical Center University Clinic&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ltd ` Medulla - Chemotherapy and Immunotherapy Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Health Center</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Budapest, Clinic of Medicine, Clinical Pharmacology Unit</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology)</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologia Intezet, Outpatient Ambulatory III</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1146</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Debrecen, Oncology Clinic</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs - Szatmár - Bereg megyei Kórházak és Egyetemi Oktatókórház</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markusovszky Lajos Teaching Hospital</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Centre</name>
      <address>
        <city>Kefar Saba</city>
        <zip>44299</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Baruch Padeh Medical Centre</name>
      <address>
        <city>Poriya</city>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Zefat</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalny Szpital Specjalistyczny</name>
      <address>
        <city>Grudziądz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dzienny Oddział Chemioterapii</name>
      <address>
        <city>Racibórz</city>
        <zip>47-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki im. dr. Ludwika Rydygiera w Suwałkach</name>
      <address>
        <city>Suwałki</city>
        <zip>16-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki im. Kardynała Stefana Wyszyńskiego w Łomży</name>
      <address>
        <city>Łomża</city>
        <zip>18-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2012</study_first_submitted>
  <study_first_submitted_qc>November 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2012</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

